Identification of Disparities in Personalized Cancer Care—A Joint Approach of the German WERA Consortium

Florian Lüke(University Hospital Regensburg), Alexander Kerscher(Comprehensive Cancer Center Mainfranken), Frank Jordan(University of Augsburg), Ralf Huss(University Hospital Augsburg), Katja Maurus(University of Würzburg), Florian Haller(Universitätsklinikum Erlangen), Hermann Einsele(Universitätsklinikum Würzburg), Bruno Märkl(University of Augsburg), Christoph Schubart(Friedrich-Alexander-Universität Erlangen-Nürnberg), Matthias Evert(University of Regensburg), Ralf C. Bargou(Max Delbrück Center), Alexander Scheiter(University of Regensburg), Norbert Meidenbauer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Silvia Spoerl(Universitätsklinikum Erlangen), Lars Tögel(Friedrich-Alexander-Universität Erlangen-Nürnberg), Matthias W. Beckmann(Universitätsklinikum Erlangen), Martin Trepel(University of Augsburg), Andreas Rosenwald, Arndt Hartmann(Universitätsklinikum Erlangen), Michaela Metz(Comprehensive Cancer Center Mainfranken), Felix Keil(University of Vienna), Sebastian Dintner(University of Augsburg), Elena Hartmann(University of Würzburg), Sabine Einhell(University of Regensburg), Kirsten Utpatel(University of Regensburg), Rainer Claus(University of Augsburg), Daniela Sparrer(University Hospital Regensburg), Wolfgang Dietmaier(University of Regensburg), Volker Kunzmann(University of Würzburg), Ulrich Kaiser(University of Applied Sciences Landshut), Stephanie Brändlein(University of Würzburg), Markus Krebs(Comprehensive Cancer Center Mainfranken), Andréas Mackensen(University Medical Center Freiburg), Tobias Pukrop(University Hospital Regensburg), Mithun Scheytt(Comprehensive Cancer Center Mainfranken), Sebastian Sommer(University of Augsburg), Maria-Elisabeth Goebeler(Universitätsklinikum Würzburg), Diana Haake(Comprehensive Cancer Center Mainfranken), Wolfgang Herr(University Hospital Regensburg), Daniel Heudobler(University of California San Diego)
Cancers
October 14, 2022
10.3390/cancers14205040
Cited by 26

Related Papers

Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k